Turn Therapeutics Reports Q1 Results, Boosts Cash to $11.2M, Addresses Going Concern

summarizeSummary

Turn Therapeutics reported its first quarter 2026 financial results, showing a significant increase in cash and cash equivalents to $11.2 million, largely due to the recently secured $7 million growth capital. This improved liquidity directly addresses the company's previously disclosed going concern risk and supports the advancement of its lead clinical program.

check_boxKey Events

• Cash Position Significantly Improved

  Cash and cash equivalents increased to $11.2 million as of March 31, 2026, up from $5.08 million at December 31, 2025. This substantial increase in liquidity is critical for a company that recently disclosed going concern doubts.

• Avenue Capital Funding Confirmed

  The initial $7 million tranche of the growth capital facility with Avenue Capital Group was funded on March 24, 2026, providing access to up to $25 million. This funding was previously announced on March 24, 2026, and is now reflected in the Q1 balance sheet.

• Increased Net Loss

  The company reported a net loss of $(970,972) for Q1 2026, compared to a net loss of $(328,547) for Q1 2025, indicating higher operating expenses.

• Lead Clinical Program on Track

  The Phase 2 trial for GX-03 in moderate-to-severe atopic dermatitis remains on schedule, with an interim assessment expected in Q2 2026 and topline results anticipated in mid-2026.

auto_awesomeAnalysis

This filing is highly important as Turn Therapeutics, which previously disclosed substantial doubt about its ability to continue as a going concern in its 10-K on March 31, 2026, has significantly improved its cash position. The increase in cash and cash equivalents to $11.2 million from $5.08 million directly addresses the immediate liquidity concerns and extends the company's operational runway. While the net loss increased, the successful funding of the initial tranche of the Avenue Capital facility provides critical capital for ongoing clinical programs, including the GX-03 Phase 2 trial, which remains on track for topline results in mid-2026.